Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Basic fibroblast growth factor prevents thalamic degeneration after cortical infarction.

K Yamada1, A Kinoshita, E Kohmura

  • 1Department of Neurosurgery, Osaka University Medical School, Japan.

Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism
|May 1, 1991
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bone-destructive osseous arteriovenous fistula at the jugular bulb mimicking a glomus jugular tumor.

Neuro-Chirurgie·2021
Same author

New proposal to revise the classification for squamous cell carcinoma of the external auditory canal and middle ear.

The Journal of laryngology and otology·2021
Same author

Mice with cleavage-resistant N-cadherin exhibit synapse anomaly in the hippocampus and outperformance in spatial learning tasks.

Molecular brain·2021
Same author

Successful treatment with cyclosporine and anti-tumour necrosis factor agent for deficiency of adenosine deaminase-2.

Scandinavian journal of rheumatology·2020
Same author

DWI for Monitoring the Acute Response of Malignant Gliomas to Photodynamic Therapy.

AJNR. American journal of neuroradiology·2019
Same author

Three-dimensional shaping technique for coil placement using the steam-shaped microcatheter for ruptured blood blister-like aneurysm.

Neuro-Chirurgie·2018

Basic fibroblast growth factor (bFGF) prevents thalamic atrophy after middle cerebral artery (MCA) occlusion in rats. This neuroprotective effect preserves thalamic neurons and increases astrocyte activity, offering potential therapeutic strategies for stroke recovery.

Area of Science:

  • Neuroscience
  • Regenerative Medicine
  • Stroke Research

Background:

  • Focal infarction of the middle cerebral artery (MCA) in rats leads to progressive thalamic atrophy via retrograde degeneration.
  • Thalamic atrophy significantly impacts neurological function following ischemic stroke.

Purpose of the Study:

  • To investigate the potential of basic fibroblast growth factor (bFGF) to prevent thalamic atrophy in a rat model of MCA occlusion.
  • To evaluate the effects of bFGF on neuronal survival and astrocyte activation in the context of ischemic injury.

Main Methods:

  • Establishment of a focal infarction model by occluding the left MCA in rats.
  • Intracisternal administration of recombinant bFGF or vehicle solution to experimental groups.
  • Histological and computerized cell size analysis of thalamic tissue at 28 days post-occlusion.

Related Experiment Videos

  • Assessment of astrocyte activation via glial fibrillary acidic protein (GFAP) staining in separate experiments.

    • Main Results:

    • bFGF treatment significantly preserved the posterior ventral thalamus area (93% of contralateral) compared to vehicle treatment (75%).
    • Histological analysis revealed preservation of thalamic neurons in bFGF-treated rats, contrasting with neuronal shrinkage and loss in controls.
    • bFGF administration led to a significant increase in GFAP-positive astrocytes in normal rats, suggesting a role in modulating glial response.

    Conclusions:

    • Intracisternal bFGF administration effectively prevents retrograde thalamic atrophy following MCA occlusion in rats.
    • bFGF demonstrates neuroprotective properties by preserving thalamic neurons and potentially modulating astrocyte activity.
    • These findings highlight bFGF as a promising therapeutic agent for mitigating secondary brain damage after ischemic stroke.